Massimo Aglietta

Q: What Schools Are Affiliated With Massimo Aglietta

Massimo Aglietta is affiliated with the following schools: University of Milan, University of Turin, Seoul National University

Massimo Aglietta's AcademicInfluence.com Rankings

Massimo Aglietta

Physics

#6598

World Rank

#8562

Historical Rank

Particle Physics

#317

World Rank

#334

Historical Rank

physics Degrees

Download Badge

Physics

Massimo Aglietta's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Massimo Aglietta Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Massimo Aglietta's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (2012) (1608)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. (2018) (1231)
Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate (1989) (642)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. (2007) (570)
A comparison of allografting with autografting for newly diagnosed myeloma. (2007) (510)
Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. (1997) (460)
The release of platelet-activating factor from human endothelial cells in culture. (1983) (411)
Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. (2001) (334)
Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. (1999) (300)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. (2012) (297)
Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow (2006) (286)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. (2015) (253)
Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging (2004) (236)
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. (1981) (219)
Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. (1986) (210)
Correlations between diffusion-weighted imaging and breast cancer biomarkers (2012) (208)
Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. (1987) (171)
PARP Inhibitors in Ovarian Cancer. (2018) (169)
Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma (2006) (166)
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas (2010) (164)
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways (2009) (160)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (157)
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. (2013) (157)
Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. (1989) (144)
High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. (2002) (143)
Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival (2006) (143)
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors (2012) (141)
Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation (1998) (138)
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. (2011) (133)
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. (2005) (126)
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. (2006) (126)
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study (2021) (119)
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study) (2016) (116)
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. (2010) (113)
Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. (2008) (111)
Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. (1995) (107)
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity (2007) (103)
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. (2019) (101)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (101)
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models (2013) (101)
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. (2011) (97)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (96)
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (92)
Metastatic breast cancer subtypes and central nervous system metastases. (2014) (92)
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. (2002) (90)
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer (2011) (89)
Human endothelial cells are targets for platelet-activating factor (PAF). Activation of alpha and beta protein kinase C isozymes in endothelial cells stimulated by PAF. (1994) (88)
Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. (2003) (88)
Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. (1995) (87)
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. (2004) (81)
Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors (2008) (81)
Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features (2013) (80)
Combined first‐stage hepatectomy and colorectal resection in a two‐stage hepatectomy strategy for bilobar synchronous liver metastases (2010) (80)
Induction gemcitabine and oxaliplatin therapy followed by a twice‐weekly infusion of gemcitabine and concurrent external‐beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer (2013) (79)
Translocation-related sarcomas. (2009) (78)
GAS6 inhibits granulocyte adhesion to endothelial cells. (1998) (78)
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. (2005) (77)
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity (2017) (75)
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma (2005) (73)
Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases (2006) (72)
Evolution of the Experimental Models of Cholangiocarcinoma (2020) (72)
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. (2013) (70)
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer (2014) (70)
GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. (1997) (70)
Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). (2018) (67)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (66)
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study (2011) (66)
TGFα expression impairs Trastuzumab-induced HER2 downregulation (2005) (65)
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. (2014) (65)
Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer (2007) (64)
Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. (2012) (64)
Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells (1986) (64)
The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. (2012) (62)
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? (2016) (61)
Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. (1996) (60)
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis (2007) (60)
Biosynthesis and release of platelet-activating factor from human monocytes. (1983) (60)
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). (2011) (57)
In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution. (2003) (57)
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. (2010) (56)
Hormone‐receptor expression and activity of trastuzumab with chemotherapy in HER2‐positive advanced breast cancer patients (2012) (56)
Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. (2016) (55)
Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E1. (1980) (54)
In vivo effect of human granulocyte-macrophage colony-stimulating factor on megakaryocytopoiesis. (1991) (54)
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. (2009) (54)
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib (2011) (54)
Trastuzumab-based combination therapy for breast cancer (2004) (52)
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. (2018) (52)
Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. (1985) (51)
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation (2009) (50)
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications (2019) (49)
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. (2006) (49)
A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer (2004) (49)
Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. (2018) (47)
Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? (2011) (47)
Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer: A Pilot Phase II Study (2003) (47)
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 (2018) (47)
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (2021) (47)
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. (2017) (46)
Phase II Trial of Primary Radiation Therapy and Concurrent Chemotherapy for Patients with Locally Advanced Pancreatic Cancer (2005) (45)
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. (2020) (45)
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models (2017) (45)
Next generation immune-checkpoints for cancer therapy. (2018) (45)
Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. (2007) (43)
Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor. (1997) (43)
Biliary tract carcinomas: from chemotherapy to targeted therapy. (2013) (43)
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. (2006) (43)
No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. (2011) (42)
HEMATOPOIESIS Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD 34 1 Cord Blood Cells After Ex Vivo Expansion : Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells (1999) (42)
Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer (2014) (42)
Poor prognosis osteosarcoma: new therapeutic approach (2008) (41)
Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. (1996) (40)
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet‐derived growth factor receptor‐α or ‐β (2011) (39)
Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells. (2000) (39)
The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer (2019) (38)
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. (2004) (38)
Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis. (1989) (37)
PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (37)
Fast But Durable Megakaryocyte Repopulation and Platelet Production in NOD/SCID Mice Transplanted with Ex‐Vivo Expanded Human Cord Blood CD34+ Cells (2004) (37)
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. (2015) (36)
Responsiveness of highly enriched CFU-GM subpopulations from bone marrow, peripheral blood, and cord blood to hemopoietic growth inhibitors. (1991) (36)
The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. (1996) (35)
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation (2016) (35)
Recent advances in the development of breast cancer vaccines (2014) (34)
Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture. (1987) (34)
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (34)
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases (2013) (33)
Effect of acidic and basic isoferritins on in vitro growth of human granulocyte-monocyte progenitors. (1986) (33)
Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. (2005) (33)
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy (2019) (33)
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient (2015) (33)
Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer (2005) (32)
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells (2018) (32)
A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer (2005) (32)
COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. (2020) (32)
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen (2016) (32)
Adoptive immunotherapy against ovarian cancer (2016) (32)
Genitourinary tumors, non-prostate (2012) (31)
Fluoropyrimidine-induced cardiotoxicity. (2018) (31)
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. (2012) (31)
Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. (2009) (31)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. (2019) (30)
Ex vivo expansion of hematopoietic cells and their clinical use. (1998) (30)
Short‐term administration of granulocyte‐macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs (1993) (30)
HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. (2003) (30)
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. (2008) (29)
Interleukin-3 in vivo : kinetic of response of target cells (1993) (29)
Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells (2016) (29)
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients (2006) (28)
Relevance of recruitment-synchronization in the scheduling of 1-beta-D-arabinofuranosylcytosine in a slow-growing acute myeloid leukemia of the rat. (1979) (28)
Detection of basophils growing in semisolid agar culture. (1981) (28)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. (2020) (28)
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours (2019) (28)
Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. (2003) (28)
Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach (2006) (27)
Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. (2018) (27)
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. (1986) (27)
Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. (2009) (27)
Continuation of trastuzumab beyond disease progression. (2005) (27)
Expression of the c‐ErbB‐2/HER2 proto‐oncogene in normal hematopoietic cells (2003) (27)
Screening for the FIG‐ROS1 fusion in biliary tract carcinomas by nested PCR (2014) (26)
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. (2015) (26)
Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. (2021) (26)
Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. (2005) (26)
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry (2013) (26)
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. (2009) (26)
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? (2021) (26)
Involvement of a serine protease in the synthesis of platelet‐activating factor by endothelial cells stimulated by tumor necrosis factor‐α or interleukin‐1α (1994) (26)
Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. (1986) (26)
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. (2014) (25)
153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. (2012) (25)
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. (2017) (25)
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (25)
Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. (2001) (25)
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study (2018) (25)
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers (2012) (25)
Vasculogenic potential of long term repopulating cord blood progenitors (2004) (24)
Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction (2001) (24)
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers (2019) (23)
Interleukin-3 in vivo: kinetic of response of target cells. (1993) (23)
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. (2019) (23)
Opposite effect of tumor necrosis factor alpha on granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-dependent growth of normal and leukemic hemopoietic progenitors. (1990) (23)
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma (2015) (23)
Essential thrombocythemia: impaired regulation of megakaryocyte progenitors. (1991) (23)
Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. (1996) (22)
Anticoagulation for central venous catheters in patients with cancer. (2014) (22)
In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells. (1991) (21)
Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin’s lymphoma: a case report and review of the literature (2014) (21)
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience (2018) (21)
DISAPPEARANCE OF PHILADELPHIA CHROMOSOME AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR TREATMENT OF CHRONIC MYELOID LEUKAEMIA IN ACUTE CRISIS (1982) (21)
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. (2019) (21)
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy (2004) (21)
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II) (2019) (21)
Melanoma Brain Metastases in the Era of Target Therapies: An Overview (2020) (20)
Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors (1991) (20)
Role of interferon in melanoma: old hopes and new perspectives (2017) (20)
Front‐line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group (2017) (20)
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody (2018) (20)
In-vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. (1985) (20)
An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. (2009) (20)
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells (2003) (20)
Granulocyte‐Macrophage colony stimulating factor and interleukin 3: Target cells and kinetics of response in vivo (1993) (20)
Cytokine receptors, growth factors and cell cycle in human bone marrow and peripheral blood hematopoietic progenitors. (1997) (19)
High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. (1993) (19)
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine (2019) (19)
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. (2012) (19)
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. (2018) (19)
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. (2011) (18)
Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas (2012) (18)
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective (2014) (18)
Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients (2012) (18)
Breast Cancer Research and Treatment (2004) (18)
Differential effect of transforming growth factor beta 1 on the proliferation of human lymphoid and myeloid leukemia cells. (1991) (18)
Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. (2014) (18)
Ex Vivo Expansion of Cord Blood Progenitors (1998) (18)
Emerging molecular target antagonists for the treatment of biliary tract cancer (2018) (17)
Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. (2008) (17)
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study (2021) (17)
Jaw complications in breast and prostate cancer patients treated with zoledronic acid (2006) (17)
Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an Italian expert panel (2011) (17)
Aromatase inhibitors as adjuvant therapy for breast cancer. (2009) (17)
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. (2020) (17)
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice (2017) (16)
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses (2019) (16)
In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy (2012) (16)
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. (2007) (16)
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison (2010) (16)
In vivo priming of human normal neutrophils by granulocyte‐macrophage colony stimulating factor: effect on the production of platelet activating factor (1990) (16)
Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl (1997) (16)
Rationale for the use of granulocyte-macrophage colony-stimulating factor in oncology. (1994) (16)
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma (2016) (16)
A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. (2012) (15)
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes (2020) (15)
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial. (2008) (15)
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer (2016) (15)
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity (2016) (14)
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. (2020) (14)
A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients (2015) (14)
Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes. (1988) (14)
The role of c‐Mpl ligands in the expansion of cord blood hematopoietic progenitors (1998) (14)
Flow cytometric detection and quantitative analysis of the GM-CSF receptor in human granulocytes and comparison with the radioligand binding assay. (1996) (14)
Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. (1986) (14)
Autologous bone marrow transplantation in acute leukemia. (1987) (14)
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. (2013) (14)
Alpha–fetoprotein elevation in NUT midline carcinoma: a case report (2017) (14)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. (2019) (14)
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). (2013) (14)
Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas? (2003) (14)
Melanoma and other skin tumors (2012) (13)
ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. (2012) (13)
Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no‐transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986 (1993) (13)
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. (2010) (13)
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor. (1995) (13)
Retinoic acid enhances the growth of only one subpopulation of granulomonocyte precursors. (1984) (13)
Short term treatment with Escheria coli recombinant human granulocyte‐macrophage–colony stimulating factor prior to chemotherapy for Hodgkin disease (2000) (13)
Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study (2002) (13)
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (12)
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma (2018) (12)
The involvement of human-nuc gene in polyploidization of K562 cell line. (2000) (12)
Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. (2014) (12)
Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott‐Aldrich Syndrome Gene (2009) (12)
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights (2020) (12)
Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART) (2013) (12)
PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY (2019) (12)
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer. (2012) (11)
Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update. (2021) (11)
484PDAnalysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142 (2017) (11)
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR (2018) (11)
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
Feasibility of cord blood stem cell manipulation with high-energy shock waves: an in vitro and in vivo study. (2005) (11)
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. (2017) (11)
Adoptive immunotherapy against sarcomas (2015) (11)
Sustained Long‐Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Third‐Generation Lentiviral Vectors (2008) (11)
Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group. (1989) (11)
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients. (2013) (10)
Allogeneic hemopoietic stem cell transplantation in solid tumors. (2005) (10)
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line (2016) (10)
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? (2019) (10)
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study (2008) (10)
Treatment of metastatic melanoma: a multidisciplinary approach. (2017) (10)
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. (2019) (9)
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models (2014) (9)
Androgen receptor status predicts development of brain metastases in ovarian cancers (2017) (9)
Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival. (2004) (9)
Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study (2012) (9)
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. (2019) (9)
PALETTE : Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients (2012) (9)
Trastuzumab beyond disease progression: case closed? (2009) (9)
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors. (1995) (9)
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (2012) (9)
Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab (2008) (8)
[Prevention and treatment of febrile neutropenia]. (1997) (8)
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives (2019) (8)
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells (2015) (8)
Serial Transplantations in Nonobese Diabetic/Severe Combined Immunodeficiency Mice of Transduced Human CD34+ Cord Blood Cells: Efficient Oncoretroviral Gene Transfer and Ex Vivo Expansion Under Serum‐Free Conditions (2006) (8)
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-lnduced Killer Cells (2017) (8)
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. (2019) (8)
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. (2002) (8)
Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability (2003) (8)
Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. (2007) (8)
High-risk osteosarcoma (OS): Preliminary results of the ISG-SSG II protocol (2005) (8)
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer (2010) (8)
Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142 (2018) (7)
Gingival metastasis of a radiotherapy-induced breast angiosarcoma: diagnosis and multidisciplinary treatment achieving a prolonged complete remission. (2012) (7)
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. (2021) (7)
Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients (Cancer (2009) 115, (2980-2987)) (2009) (7)
CSFs, from basic science to clinical trials. (1989) (7)
Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy (2005) (7)
A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient (2021) (7)
Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. (2017) (7)
A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer. (2010) (7)
Trastuzumab treatment in breast cancer. (2006) (7)
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? (2011) (7)
Differences in the in vitro growth pattern of fresh and cryopreserved granulo-monopoietic precursors. (1984) (7)
Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures (2020) (7)
Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors (2021) (7)
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO (2022) (7)
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer. (2016) (7)
Ex vivo expansion of megakaryocytes. (2000) (7)
Activation of JAK 2 in Human Vascular Endothelial Cells by Granulocyte-Macrophage Colony-Stimulating Factor (1997) (7)
Controversies in breast cancer: adjuvant and neoadjuvant therapy (2005) (6)
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective (2021) (6)
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report (2016) (6)
Acute pulmonary failure after the first administration of recombinant human granulocyte-macrophage colony-stimulating factor. (1992) (6)
Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. (2006) (6)
A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. (2015) (6)
Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients (2021) (6)
GM-CSF: intravenous versus subcutaneous treatment. (1990) (6)
Veliparib: a new therapeutic option in ovarian cancer? (2019) (6)
Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report. (2003) (6)
Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma. (2005) (6)
[Diagnostic approach to the anemic cancer patient]. (1997) (6)
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index (2021) (6)
High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. (2000) (6)
Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. (1987) (6)
Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. (1991) (6)
Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study) (2019) (6)
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives (2015) (6)
Effects of Human FLT 3 Ligand on Myeloid Leukemia Cell Growth : Heterogeneity in Response and Synergy With Other Hematopoietic Growth Factors (2000) (6)
Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer (2006) (6)
Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma. (2021) (5)
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III) (2021) (5)
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. (2007) (5)
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer (2017) (5)
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study (2020) (5)
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers (2020) (5)
Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha. (1994) (5)
Treating breast cancer with cell-based approaches: an overview (2017) (5)
MYELOFIBROSIS AND PROSTAGLANDINS: EFFECT OF PROSTAGLANDIN E1 ON COLONY‐FORMING CELLS (CFU‐GM) (1981) (5)
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients (2021) (5)
In vitro reappearance of myeloid progenitors killed by mafosfamide. (1987) (5)
Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (5)
Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. (2018) (5)
Comparison of endorectal magnetic resonance imaging, clinical prognostic factors and nomograms in the local staging of prostate cancer patients treated with radiotherapy. (2008) (5)
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. (2021) (5)
The relevance of cell kinetics for optimal scheduling of 1-β-d-Arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML) (2004) (5)
A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study. (2016) (5)
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer (2018) (5)
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial (2021) (5)
Targeted agents: how can we improve the outcome in biliary tract cancer? (2013) (4)
Normal and leukaemic granulopoiesis. (1981) (4)
Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. (1991) (4)
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients (2019) (4)
Human GM-CSF in vivo: identification of the target cells and of their kinetics of response. (1990) (4)
A nonrandomized phase II trial of sorafenib (S) and everolimus (E) in unresectable metastatic osteosarcoma (OST) patients (pts) relapsed after standard chemotherapy. (2014) (4)
Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. (2011) (4)
Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience (2019) (4)
"Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. (2019) (4)
Comparison of Endorectal Magnetic Resonance Imaging, Clinical Prognostic Factors and Nomograms in the Local Staging of Prostate Cancer Patients Treated with Radiotherapy (2008) (4)
Effect of Hemopoietic Growth Factors on the Proliferation of Acute Myeloid and Lymphoid Leukemias. (1990) (4)
[Prevalence of anemia in oncologic patients treated with chemotherapy. Italian survey at the national level]. (2001) (4)
Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016. (2019) (4)
OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018 (2019) (4)
An in vitro study of basophil production in chronic myeloproliferative disorders. (1984) (4)
A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. (1995) (4)
HER2 and central nervous system metastasis in patients with breast cancer. (2004) (4)
Improvement of metastatic colorectal cancer patient survival: Single institution experience. (2018) (4)
2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab) (2015) (4)
Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors (2022) (4)
Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: The value of early evaluation of the course of the disease (2005) (4)
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer (2020) (4)
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL). (1991) (3)
What can we learn from the ZOOM trial?--Authors' reply. (2013) (3)
[The use of erythropoietin alpha in programs of high-dose chemotherapy]. (2000) (3)
Bone metastases in biliary cancers: A multicenter retrospective survey (2018) (3)
Preventing Venous Thromboembolism in Patients with Cancer. (2019) (3)
Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma (2022) (3)
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma (2022) (3)
Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). (2004) (3)
BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report (2017) (3)
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks (2011) (3)
A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study. (2015) (3)
Duration of trastuzumab for HER2-positive breast cancer. (2013) (3)
Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. (2017) (3)
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL (2007) (3)
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma (2021) (3)
Non-linear relationship between HER-2 expression and response to trastuzumab in breast cancer cells. (2006) (3)
Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy. (2014) (3)
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP) (2013) (3)
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination (2022) (3)
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma (2014) (3)
Oncology in the nineties: from genes to therapy. (1991) (3)
Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts). (2016) (3)
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy (2015) (3)
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature. (2012) (3)
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy (2021) (3)
Abstract PD10-07: Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients (2010) (2)
Abstract P1-08-23: Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer (2013) (2)
Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma (2007) (2)
D26Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL (2016) (2)
Responsiveness to prostaglandin E1 of different subtypes of normal and pathological committed granulomonopoietic precursors. (1983) (2)
Increase of creatine kinase value (CK) correlates with muscoloskeletal complaints (MSC) in GIST patients during imatinib therapy. (2006) (2)
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial (2020) (2)
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis (2021) (2)
Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST). (2011) (2)
Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018. (2019) (2)
LIMITED GRAFT-VERSUS MYELOMA EFFECT AFTER LOW-DOSE TBI BASED NON-MYELOABLATIVE ALLOGRAFTING EMPLOYED AS SALVAGE TREATMENT COMPARED TO FIRST LINE TREATMENT (2006) (2)
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients (2021) (2)
An update of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. (2007) (2)
Adjuvant chemotherapy following curative intent hepatectomy for intrahepatic cholangiocarcinoma: Results from a multi-institutional analysis of 575 patients. (2012) (2)
A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-{alpha} or -{beta} (PDGFR-{alpha}/PDGFR-{beta}): An Italian Sarcoma Group study. (2010) (2)
3*A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab (2015) (2)
Response to Eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. (2020) (2)
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) (2012) (2)
Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer? (2007) (2)
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) (2021) (2)
Positive and negative signals in the control of myelopoiesis. (1989) (2)
The release of platelet-activating factor during phagocytosis by polymorphonuclear neutrophils and monocytes. (1982) (2)
Autologous bone marrow transplantation and pharmacological bone marrow purging: in vitro use of maphosphamide and bleomycin. (1988) (2)
Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis. (2020) (2)
Preclinical activity of lenalidomide in metastatic colorectal cancer. (2013) (2)
Effect of high doses of cytostatic drugs on cell kinetics of the acute myeloid leukemia of the BN rat and of human AML (1979) (2)
Patient self-evaluation of side-effects related to adjuvant chemotherapy in breast cancer: A prospective study. (2015) (2)
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy (2021) (2)
Correlation of 11C-choline PET and PSA values in patients with prostate cancer and biochemical relapse after primary treatments (2007) (2)
Atypical myeloproliferative disorder associated with a 21 trisomic clone (1981) (1)
The 41st Annual Meeting of The American Society of Clinical Oncology (2005) (1)
1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile (2021) (1)
Vascular Endothelial Growth Factor and Its Receptor KDR/flk-1 Play Important Roles in Hematopoiesis. (2001) (1)
Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemia—Mafosfamide Italian Study Group (1988) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Abstract 5551: Antitumor activity, gene and miRNA modulation upon ET-743 treatment in an intrahepatic cholangiocarcinoma patient-derived xenograft model (2014) (1)
Trastuzumab in the adjuvant setting: A practical review (2011) (1)
CFU-C and prognosis in a case of posthepatitic aplastic anaemia. (1978) (1)
Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo. (2012) (1)
448P Predictive factor of cardiotoxicity in fluoropyrimidine-treated colorectal cancer patients: Interim analysis of the prospective observational CHECKPOINT trial (2020) (1)
Effect of AZD0530 (saracatinib) on biliary cancer cell motility and invasion. (2011) (1)
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells (2015) (1)
Imaging tumor response to therapy (2012) (1)
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation (2016) (1)
Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models (2021) (1)
Prostaglandins and myelopoiesis: effect of prostaglandin E1 on normal and chronic myeloid leukemia colony forming cells (CFU-GM) subpopulations. (1981) (1)
Human gamma interferon modifies C-myc expression and growth pattern of U937 cell line but not of its subclone 1937 (1986) (1)
1131 POSTER Osteonecrosis of the jaw (ONJ) in patients treated with Bisphosphonates (BP): the experience of the "Rete Oncologica di Piemonte e Valle D'Aosta" (North-Western Italy) (2007) (1)
Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312) (2019) (1)
Postoperative nomogram for predicting survival after resection for intrahepatic cholangiocarcinoma. (2013) (1)
Anthracycline-based adjuvant chemotherapy in breast cancer (2010) (1)
A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. (2007) (1)
Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS). (2010) (1)
Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities. (2011) (1)
Mafosfamide and bleomycin purging effects on normal marrow and K562 cells (1986) (1)
Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial (2003) (1)
70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial (2023) (1)
Tumor control with palliative external beam radiation therapy (EBRT) in advanced and unresectable osteosarcoma (OS) progressing after standard treatment. (2019) (1)
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry (2008) (1)
Target cells for GM-CSF and kinetics of response. (1990) (1)
Outcome of patients with HER2+ advanced breast cancer (ABC) progressing during trastuzumab (T)-based treatment (2005) (1)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (1)
Positron-emission tomography in cancer therapy. (2006) (1)
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST (2022) (1)
Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cell for patients with osteosarcoma with bone metastasis. (2011) (1)
Colony stimulating activity (CSA) in human adult and cord blood. Interaction between leucocytes and plasma. (1980) (1)
A risk-based individualized follow-up after complete surgery as an effective procedure to reduce the relapse (R) impact in GIST patients (pts). (2013) (1)
Effect of lithium on normal and chronic granulocytic leukemia colony forming cells (CFU-GM) (1981) (1)
Abstract C213: Sorafenib blocks tumor growth, angiogenesis, and metastatic potential in preclinical models of osteosarcoma through the inhibition of ERK1/2, MCL‐1, and ezrin pathways (2009) (1)
MIC A/B Protein Expression Associates with Trastuzumab-Resistant Breast Cancer Cells Leading to Effective Immunotherapy by Cytokine Induced Killer Cells. (2009) (1)
Modulation by retinoic acid of the growth of bone marrow cell progenitors from patients with myelodysplastic syndrome. (1989) (1)
The Tyrosine Kinase c-Met Is Selectively Expressed on Motile Hematopoietic Progenitors Following G-CSF Administration and Promotes Mobilization by Regulating Stem Cell Niche Components. (2006) (1)
Megakaryocyte differentiation and reconstitution in nod/scid mice of CD34+ cord blood cells after extensive ex vivo expansion (2000) (1)
Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC). (2011) (1)
Abstract P6-10-09: Mutational landscape of breast cancer patients in ROME trial: preliminary results (2023) (1)
1633P Explorative model of imatinib resistant wild type GIST and potential immunotherapy strategies (2020) (0)
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies (2017) (0)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (0)
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study (2022) (0)
A09Self-evaluation subjective toxicity according to the Common Toxicity Criteria in breast cancer patients undergoing adjuvant chemotherapy: final results of an Italian prospective study (2015) (0)
Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016. (2018) (0)
Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients (2016) (0)
Subject Index Vol. 69, 1983 (1983) (0)
ONE-HUNDRED-EIGHT CONSECUTIVE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THE TANDEM AUTO-TBI BASED MINI-ALLO APPROCH (2006) (0)
H2 receptor antagonists and human granulopoiesis (1985) (0)
Impact of the pandemic on surgical oncology in Piedmont, Italy: a retrospective observational study (2022) (0)
H15Rare epidermal growth factor receptor (EGFR) mutations in a 425 patients population with non-small cell lung cancer (NSCLC): clinical, molecular and survival data. The IRCCS Candiolo experience (2015) (0)
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference (2007) (0)
14 The status of bone marrow transplant clinical trials (2003) (0)
[GM-CSF: target cells and their response kinetics]. (1989) (0)
Abstract 3591: CSPG4 as innovative target for CAR redirected CIK lymphocytes against soft tissue sarcomas (2018) (0)
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy (2022) (0)
Hemopoietic growth factor-independent TGFβ1 inhibition of human acute myeloid leukemia cell growth (1995) (0)
TANDEM AUTO-MINI ALLO APPROACH FOR NEWLY DIAGONSED MULTIPLE MYELOMA: AN UPDATE OF THE ITALIAN EXPERIENCE (2005) (0)
Interleukin 1 induces biosynthesis of platelet activating factor in human endothelial cells by deacylation/reacetylation process (1987) (0)
Preoperative Tru-Cut biopsy (POB) for the diagnosis of retroperitoneal soft tissue sarcomas (RPS) and risk of local recurrence (LR) compared to primary surgery of the tumor. (2017) (0)
Efficacy and Safety of Ipilimumab Reinduction Therapy Patients with Pretreated Advanced Melanoma Participating in an Expanded Access Programme (EAP) in Italy (2012) (0)
Antitumor activity of sorafenib in osteosarcoma (OS) preclinical models (2008) (0)
Induction of differentiation: a possible therapeutic approach to the treatment of hematologic malignancy (1987) (0)
763P Treatment response to non-platinum therapies in ovarian cancer patients according to BRCA status: A retrospective analysis of a large multicentric cohort (2021) (0)
Activation of immune response in refractory patients to standard treatment (T.R.A.N.S.L.A.T.E.) (2018) (0)
Underuse of anthracyclines in women with HER2-positive advanced breast cancer. (2010) (0)
Risk of adverse cardiovascular events (CVE) and incident diabetes mellitus (DM) in patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT): A meta-analysis of adjusted observational results. (2012) (0)
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers (2022) (0)
164. Effect of recombinant human stem cell factor on the proliferation and differentiation in vitro of hemopoietic progenitors in myeiodisplastic syndromes (1992) (0)
Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient. (2004) (0)
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma (2015) (0)
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model (2022) (0)
LEUCEMIA MIELOIDE CRONICA (Sindromi Mieloproliferative Crioniche) (2000) (0)
INCIDENCE OF INVASIVE ASPERGILLOSIS IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS: AN ITALIAN PROSPECTIVE MULTICENTER STUDY (2004) (0)
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models (2017) (0)
Abstract A82: HHER2‐positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib (2009) (0)
Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma (2006) (0)
Abstract 3234: PD-1 is intrinsically expressed by lung cancer cells with stemness features inhibited by PD-1 blockade (2019) (0)
Metastases outside the abdomen (MOA) are associated with initial high tumor burden (TB) in gastrointestinal stromal tumors (GIST). (2006) (0)
Invasive aspergillosis in allogeneic stem cell recipients: what are we doing? An Italian prospective study (2008) (0)
Role of prostaglandin E (PGE) in the regulation of normal and chronic myeloid leukemia (CML) granulopoiesis (1980) (0)
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours (2019) (0)
G1* PRIMARY CHEMORADIATION WITH FOLFOX-4 AND CETUXIMAB IN LOCALLY ADVANCED ESOPHAGEAL CANCER: PRELIMINARY DATA FROM B152 TRIAL (2008) (0)
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: Retrospective analysis of clinical outcomes. (2020) (0)
AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2003) (0)
To the editor [15] (2006) (0)
TROMBOCITEMIA ESSENZIALE (Sindromi Mieloproliferative Croniche) (2000) (0)
High-grade soft tissue sarcomas (STS) of elderly (>=70 years) patients (E-STS): Feasibility and morbidity of anthracycline-based chemotherapy (A-CT) in a selected subset of patients. (2010) (0)
P1-18-02: Descriptive Analysis of the Management of Breast Cancer Patients with a Solitary Lesion Diagnosed with 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan. (2011) (0)
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
Use of FDG-PET (PET) to select patients for metastasectomy for high-grade soft tissue sarcomas (HG-STS) (2008) (0)
Survival of metastatic colorectal cancer patients at Candiolo Cancer Institute. (2017) (0)
Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS). (2019) (0)
65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts (2020) (0)
Sustained Long Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Advanced Lentiviral Vectors in the Preence of ABC Inhibitors. (2004) (0)
Cardiac metastasis arisen from a limb grade 1 mixoid liposarcoma six years after its radical resection (2005) (0)
Microenvironment and Immunology Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue (2013) (0)
Alpha–fetoprotein elevation in NUT midline carcinoma: a case report (2017) (0)
350 Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas (2012) (0)
Low doses of ketoconazole and prednisone in patients with castration resistant prostate cancer (CRPC): A retrospective study on 73 patients. (2013) (0)
Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019 (2019) (0)
Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). (2012) (0)
Targeting The MTOR Pathway In Malignant Pleural Mesothelioma (2011) (0)
PD-006Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study (2015) (0)
Impact of upfront multidisciplinary tumor board (MTB) evaluation on breast sarcoma (BS) outcome. (2020) (0)
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index (2021) (0)
Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin’s lymphoma: a case report and review of the literature (2014) (0)
Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) (2022) (0)
Related articles (2013) (0)
Contents Vol. 69, 1983 (1983) (0)
Effects of prostaglandin E1 (PGE1) on colony forming cells (CFU-GM) subpopulations from normal subjects and from patients with chronic myeloproliferative disorders (1981) (0)
Reply to A. Sánchez-Muñoz et al (2009) (0)
Migration of neutrophils to the oral mucosa during treatment with recombinant human Granulocyte Macrophage Colony Stimulating Factor. (1992) (0)
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways (2012) (0)
The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer. (2016) (0)
Abstract 569: Expression and modulation by IFN of HLA class I APM components in melanoma: Potential biomarkers of clinical response to checkpoint inhibitors (2019) (0)
Preclinical evidence of ET-743 as a potential chemotherapy option for the treatment of biliary carcinoma. (2013) (0)
Translocation of the c-myc oncogene 3′ to the immunoglobin heavy chain enhancer in the tumor DNA from a Burkitt lymphoma (1986) (0)
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients (2021) (0)
134 Dissecting the mTOR pathway in osteosarcoma (2010) (0)
Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies. (2007) (0)
Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma. (1990) (0)
Concomitant radiation therapy does not affect adjuvant CMF delivery in patients with operable breast cancer. (2004) (0)
Blood c cell rredistribution iin tthe llung a after a administration of rrecombinant h human g granulocyte-macrophage colony-stimulating ffactor (1995) (0)
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES (2007) (0)
602 Is There a Role for Allografting in Myeloma in the Era of New Drugs?: Long-Term Follow-Up of a Comparative Study (2011) (0)
Expanded Human NKT Type II Cells: Effective Against Colon Cancer Cells, Safe across Major MHC Barriers and Successfully Expandable after Non-Myeloablative HCT for Solid Tumors. (2005) (0)
45th Annual Meeting of the Italian Cancer Society Bergamo, 9-12 November 2003 (2004) (0)
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. (2018) (0)
Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers (2008) (0)
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models (2014) (0)
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in KRAS wild-type Advanced Biliary Tract Cancer : a randomized , Phase II trial ( Vecti-BIL Study ) Running title GEMOX and Panitumumab in wt KRAS BTC (2016) (0)
Human Endothelial Cells Produce Platelet Activating Factor in Response to Interleukin 1 (1987) (0)
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab. (2016) (0)
Phase II trial of induction GEMOX followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. (2016) (0)
Abstract 3709: PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR) (2016) (0)
D28The FUNNEL: a precision medicine project for metastatic colorectal cancer (2016) (0)
Efficacy of low-dose ketoconazole in the treatment of castration-resistant prostate cancer (CRPC): A single-institution experience. (2012) (0)
Different Kinetic Pattern of Chronic Myeloid Leukemia: Lymphoblastic and Myeloblastic Blastic Crisis 1 (1980) (0)
Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience (2007) (0)
000379 CONCURRENT RADIOTHERAPY DOES NOT IMPAIR OPTIMAL DELIVERY OF ADJUVANT CMF CHEMOTHERAPY BUT INCREASES TOXICITY IN EARLY BREAST CANCER PATIENTS (2005) (0)
Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study. (2021) (0)
HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis (2022) (0)
C-reactive protein (CRP) and peripheral blood monocyte count (PBMC) in patients (pts) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (TR): correlation with progression-free survival (PFS). (2015) (0)
HSCT With Mismatch Unrelated Donor: A Comparison of ATG vs. PT-Cy-Based GvHD Prophylaxis in Pediatric and Adult Patients (2020) (0)
LOW-DOSE TBI-BASED NON-MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA (2004) (0)
NONMYELOABLATIVE ALLOGRAFTING OR AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (2007) (0)
Immunological and Genetic Biomarkers of Sarcomas (2019) (0)
Cytokineinducedkillercells asadoptiveimmunotherapy strategytoaugmentgraftversus tumorafterhematopoieticcell transplantation (2009) (0)
7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis (1987) (0)
the Amplification and Self-Renewal of Repopulating Stem Cells of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice (2013) (0)
Contents Vol. 68, 2005 (2005) (0)
Allogeneic hematopoietic cell transplantation after reduced intense conditioning as adoptive cell therapy in resistant metastatic colorectal carcinoma. The European experience. (2006) (0)
Effect of interferon-gamma on HLA class II antigen expression and sensitivity to prostaglandin E1 by normal and leukemic myeloid progenitors. (1988) (0)
Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient (2004) (0)
Efficient Oncoretroviral Gene Transfer in Primary, Secondary and Tertiary NOD/SCID Mice under Serum-Free Conditions. (2004) (0)
Subject Index Vol. 68, 2005 (2005) (0)
Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer" [Crit. Rev. Oncol. Hematol. 133 (January) (2019) 17-24]. (2020) (0)
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy (2023) (0)
Selected Highlights from the 26th San Antonio Breast Cancer Symposium (2004) (0)
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study (2021) (0)
newer imaging techniques that are sensitive to tumor biology open the way to exciting developments in this field (2012) (0)
E28Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy (2015) (0)
Abstract LB-042: Xenopatients help in redefining medical therapeutic algorithms in high risk ovarian cancer (2016) (0)
P2-12-31: Moderate Immunohistochemical Expression of HER2 (2+) without HER2 Gene-Amplification Is a Negative Prognostic Factor in Early Breast Cancer. (2011) (0)
Abstract 885: Anti-CSPG4 CAR.CIK lymphocytes are effective against advanced sarcomas in 3D spheroid and xenograft models (2020) (0)
hematopoietic progenitor cells via ROS signaling induced mobilization of - Enhanced c-Met activity promotes G-CSF (2011) (0)
Low dose TBI based non myeloablative allografting for advanced hematological malignancies: A multicenter experience. (2003) (0)
1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial (2022) (0)
Modulation of leukemic cell proliferation by tumor necrosis factor alpha. (1988) (0)
28th meeting of the Italian Cancer Society (SIC). New challenges of molecular oncology. (2002) (0)
Abstract 2298: Cytokine-induced killer cells redirected with anti-CD44v6 chimeric antigen receptor against soft tissue sarcomas (2016) (0)
Thrombopoietin-stimulated ex vivo expansion of megakakyocyte progenitors of human cord blood (1997) (0)
Imatinib in 34 patients with steroid-refractory chronic graft-versus-host-disease: final evaluation of the second prospective trial, according to the NIH Consensus criteria for cGvHD (2012) (0)
P3-07-04: Does Omission of Axillary Dissection after a Positive Sentinel Node Biopsy Influence Indication to Adjuvant Chemotherapy in Operable Breast Cancer Patients? (2011) (0)
Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines. (1989) (0)
21 STEM CELLS IN CORD AND NEONATAL BLOOD (1977) (0)
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. (2004) (0)
Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy (2009) (0)
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells (2022) (0)
Analysis of Hohn (HC) and porth-a-cath (PAC) central venous catheters (CVC) adverse events (AEs) and related costs in advanced soft tissue sarcomas (STS) treated with trabectedin (TR) 24-hour (24-h) infusion therapy. (2017) (0)
Session D: Organization D1 ORGANIZATIONAL MODEL OF CENTRALIZED PHARMACY FOR THE PREPARATION OF CANCER THERAPIES PERSPECTIVE (2004) (0)
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer (2020) (0)
133 mTOR is a druggable molecule in Malignant Pleural Mesothelioma targeted therapy: antiproliferative effect of sorafenib and everolimus in preclinical models (2010) (0)
Primitive stem cell biology (2001) (0)
L02*Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study (2015) (0)
Imaging as a potential tool for subtyping breast cancer (2012) (0)
Abstract LB-213: The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS). (2013) (0)
granulocyte-monocyte progenitors Effect of acidic and basic isoferritins on in vitro growth of human (2011) (0)
Induction chemotherapy with continuous infusion ifosfamide (IFX) and antracyclin in a high dose chemotherapy with peripheral blood stem cell (PBSC) support program in advanced soft tissue sarcomas (STS) (1999) (0)
190 Novel cellular immunotherapy with anti-mesothelin CAR-killer lymphocytes against advanced cholangiocarcinoma (2022) (0)
Role of Hematopoietic Growth Factors on the ex Vivo Expansion of Primitive Cord Blood Stem Cells (1999) (0)
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses (2019) (0)
A form to report pain assessment and monitoring in the oncology clinical record: a Delphi process. (2023) (0)
Abstract 2812: CSPG4-specific CAR.CIK lymphocyte-based immunotherapy to eliminate HLA class I-defective melanoma tumors (2022) (0)
Preclinical study of trabectedin (TR) and poly(ADP-ribose)polymerase 1 (PARP-1) inhibitor combination in soft tissue sarcoma (STS). (2017) (0)
GM-CSF and dose escalation of chemotherapy. (1994) (0)
Abstract 533: The immune landscape in colon cancer and its changes after radiotherapy (2019) (0)
Abstract P6-08-49: Do traditional prognostic factors in early breast cancer still have a role in the molecular era? (2015) (0)
F073-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA (2015) (0)
TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2007) (0)
PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (0)
Abstract 2290: Effective immunotherapy with cytokine-induced killer cells against autologous melanoma cancer stem cells (2016) (0)
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report (2016) (0)
AUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL (2002) (0)
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (2009) (0)
Errata: (Anticancer Research (2014) 34, 5 (2657)) (2014) (0)
Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report (2019) (0)
Predictive biomarkers of trabectedin (TR) and olaparib (OL) synergism in preclinical models of bone and soft tissue sarcoma (BSTS). (2014) (0)
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Massimo Aglietta?

Massimo Aglietta is affiliated with the following schools: